<DOC>
	<DOC>NCT02845089</DOC>
	<brief_summary>A retrospective observational longitudinal medical chart review study of randomly sampled patients diagnosed with advanced/metastatic NSCLC. The minimum observational period for each patient will be 12 months.</brief_summary>
	<brief_title>Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Adults 18 years and older at the time of advanced/metastatic NSCLC diagnosis, and currently alive or deceased Histologically confirmed diagnosis of advanced/metastatic NSCLC (squamous, nonsquamous or NOS) stages IIIB/IV. First diagnosis of advanced/metastatic NSCLC between 01Jan2010 and 31Mar2014 (currently alive or deceased) with a minimum 12 months of potential observation period available in medical records Medical history and treatment data must be available (or obtainable by SI) for chart abstraction from the date of advanced/metastatic diagnosis through most recent patient followup/contact. This also includes documentation of treatment by other physicians and inpatient hospital treatments within KSA or the Health Authority of Abu Dhabi (HAAD) system Patients must have at least all data on age, gender, date of advanced NSCLC diagnosis, Line of Treatment (LOT) information (agent types and dosage), and date of last followup Patient had enrolled in a cancer treatmentrelated clinical study at any time after the diagnosis of advanced/metastatic NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>